Search
Pulmonary exacerbations are associated with increased morbidity and mortality in people with cystic fibrosis (CF). There is no consensus about which outcomes should be evaluated in studies of pulmonary exacerbations or how these outcomes should be measured.
The purpose of this double-blind, randomised, controlled trial is to compare allergic outcomes in children following vaccination with acellular pertussis (aP) antigen (standard of care in Australia) given at 2 months of age versus whole cell pertussis (wP) in the infant vaccine schedule.
The Infectious Disease Implementation Research Team is a multi-disciplinary group researching the best way to implement infectious disease prevention and treatment strategies to improve the wellbeing of children and teenagers.
Christopher Asha André Dr Anita Blyth Bowen Schultz Campbell MBBS (Hons) DCH FRACP FRCPA PhD BA MBBS DCH FRACP PhD GAICD FAHMS OAM MBChB, PhD, FRACP
18 months of age infants receiving 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine will have higher antibody levels
This manuscript will give a brief overview of clinical trial design including the strengths and limitations of various approaches
Palivizumab appeared effective for reducing virologically confirmed respiratory syncytial virus in this high-risk cohort
Aboriginal children are at greater risk of rotavirus disease than non-Aboriginal children and delayed vaccine receipt is substantially higher
The aim of this study is to identify and quantify the preferences of patients with cystic fibrosis regarding treatment outcomes
Agreement between the DDD and vial-based measures of use supports the use of DDD for select antibiotics that may be targeted by antimicrobial stewardship programs